Varumärket ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN, grundat 2010 (United States), från 496 systervarumärken och 17477 konkurrerande varumärken. ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN är en del av BRISTOL-MYERS SQUIBB COMPANY, börsnoterat i New York. ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN tillhör affärsområdet Läkemedelstillverkare.
Aktiens pris och lönsamhet BRISTOL-MYERS SQUIBB COMPANY (ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN)
Köp BRISTOL-MYERS SQUIBB COMPANY-aktier med
(0 % provision och delandelar)
Ditt kapital är i riskzonen. Andra avgifter tillkommer. För mer information, besök etoro.com/trading/fees.
Investeringssimulator :
Portföljvärdering
BRISTOL-MYERS SQUIBB COMPANY
(ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN)
under 5 år*
40,83 USD
Historik på aktiemarknaden BRISTOL-MYERS SQUIBB COMPANY (ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN)
*inkluderar inte utdelningar, inkluderar inte marknadsprisordrar
tidigare prestationer påverkar inte framtida prestationer
tidigare prestationer påverkar inte framtida prestationer
